Mirae Asset Global Investments Co., Ltd. Spring Works Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$22.5 Billion
Q3 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,686 shares of SWTX stock, worth $97,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,686

Previous 2,212 21.43%

Holding current value

$97,125

Previous $83,000 3.61%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$32.04 - $42.76 $15,186 - $20,268	474 Added 21.43%	2,686 $86,000
Q2 2024 Jul 30, 2024	SELL	$36.06 - $47.62 $765,157 - $1.01 Million	-21,219 Reduced 90.56%	2,212 $83,000
Q1 2024 May 01, 2024	SELL	$36.5 - $52.5 $488,698 - $702,922	-13,389 Reduced 36.36%	23,431 $1.15 Million
Q4 2023 Jan 24, 2024	BUY	$18.94 - $37.24 $60,361 - $118,683	3,187 Added 9.48%	36,820 $1.34 Million
Q3 2023 Oct 26, 2023	SELL	$23.12 - $31.38 $56,898 - $77,226	-2,461 Reduced 6.82%	33,633 $777,000
Q2 2023 Aug 10, 2023	BUY	$23.15 - $32.71 $241,848 - $341,721	10,447 Added 40.73%	36,094 $946,000
Q1 2023 May 04, 2023	BUY	$24.97 - $34.05 $226,502 - $308,867	9,071 Added 54.72%	25,647 $660,000
Q4 2022 Feb 09, 2023	BUY	$21.73 - $28.72 $18,014 - $23,808	829 Added 5.26%	16,576 $431,000
Q3 2022 Nov 10, 2022	BUY	$24.1 - $39.66 $137,852 - $226,855	5,720 Added 57.05%	15,747 $449,000
Q2 2022 Jul 26, 2022	BUY	$18.36 - $60.07 $184,095 - $602,321	10,027 New	10,027 $247,000

Others Institutions Holding SWTX

# of Institutions

240

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.26B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Spring Works Therapeutics, Inc. Transaction History